Conventional DMARDs therapy decreases disease activity and inflammation in newly diagnosed patients with rheumatoid arthritis by increasing FoxP3, Sema-3A, and Nrp-1 gene expression.
Parviz SoufivandGhazal Hosseini TorshiziSeyed Askar RoghaniMohammad DastbazRamin LotfiBijan SoleymaniFatemeh HeydarpourZahra AbdanHosna AllahyariPublished in: Inflammopharmacology (2024)
Conventional DMARDs therapy effectively reduces disease activity and inflammation in newly diagnosed RA patients by increasing FoxP3, Sema-3A, and Nrp-1 gene expression.
Keyphrases
- disease activity
- newly diagnosed
- rheumatoid arthritis patients
- gene expression
- rheumatoid arthritis
- systemic lupus erythematosus
- ankylosing spondylitis
- juvenile idiopathic arthritis
- regulatory t cells
- oxidative stress
- dna methylation
- end stage renal disease
- chronic kidney disease
- ejection fraction
- peritoneal dialysis
- immune response
- stem cells
- cell therapy
- bone marrow
- interstitial lung disease
- mesenchymal stem cells
- idiopathic pulmonary fibrosis
- replacement therapy